Last updated: 18 July 2019 at 4:15pm EST

Daniel J Levitt Net Worth




The estimated Net Worth of Daniel J Levitt is at least $42.6 millier dollars as of 14 May 2018. Daniel Levitt owns over 3,906 units of Dynavax Technologies stock worth over $42,614 and over the last 20 years Daniel sold DVAX stock worth over $0.

Daniel Levitt DVAX stock SEC Form 4 insiders trading

Daniel has made over 2 trades of the Dynavax Technologies stock since 2012, according to the Form 4 filled with the SEC. Most recently Daniel exercised 3,906 units of DVAX stock worth $41,247 on 14 May 2018.

The largest trade Daniel's ever made was buying 100,000 units of Dynavax Technologies stock on 22 February 2012 worth over $29,000. On average, Daniel trades about 6,112 units every 134 days since 2005. As of 14 May 2018 Daniel still owns at least 3,906 units of Dynavax Technologies stock.

You can see the complete history of Daniel Levitt stock trades at the bottom of the page.



What's Daniel Levitt's mailing address?

Daniel's mailing address filed with the SEC is 11726 SAN VICENTE BLVD, SUITE 650, , LOS ANGELES, CA, 90049.

Insiders trading at Dynavax Technologies

Over the last 21 years, insiders at Dynavax Technologies have traded over $196,839,440 worth of Dynavax Technologies stock and bought 2,463,112 units worth $11,318,051 . The most active insiders traders include Andrew A. F. Hack, Partners L P/Ilbiotechnolog... et James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $1,533,390. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth $43,127.



What does Dynavax Technologies do?

dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.



What does Dynavax Technologies's logo look like?

Dynavax Technologies Corp. logo

Complete history of Daniel Levitt stock trades at LadRx Corp et Dynavax Technologies

Date
#
Société
Initié
Trans.
Transaction
Actions Prix par action Prix ​​total Actions après Source
22 Feb 2012 Daniel J Levitt
Chief Medical Officer
Acheter 100,000 $0.29 $29,000
22 Feb 2012
100,000


Dynavax Technologies executives and stock owners

Dynavax Technologies executives and other stock owners filed with the SEC include: